Phaseline

Targets › SLC12A3

SLC12A3 (Solute carrier family 12 member 3): drug programs, companies and trials

8 programs from 7 companies in 8 trials: 3 Phase 4, 3 Phase 2, 2 Phase 3; Genitourinary, Cardiovascular, Metabolic and endocrine; next expected readout Dec 2026.

Electroneutral sodium and chloride ion cotransporter, which acts as a key mediator of sodium and chloride reabsorption in kidney distal convoluted tubules. Also acts as a receptor for the pro-inflammatory cytokine IL18, thereby contributing to IL18-induced cytokine production, including IFNG, IL6, IL18 and CCL2 (By similarity). (UniProt, P55017)

Open in Phaseline: the race on SLC12A3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Chinese University of Hong KongHydrochlorothiazide
Thiazide-sensitive sodium-chloride cotransporter inhibitor
SLC12A3Phase 4HypertensionDec 2026
Icahn School of Medicine at Mount SinaiChlorthalidone
Thiazide-sensitive sodium-chloride cotransporter inhibitor
SLC12A3Phase 4Kidney StonesDec 2027
Lars RejnmarkIndapamide
Thiazide-sensitive sodium-chloride cotransporter inhibitor
SLC12A3Phase 4Hypoparathyroidism Post-surgical–
Johannes GrandMetolazone
Thiazide-sensitive sodium-chloride cotransporter inhibitor
SLC12A3Phase 3Acute Heart FailureMar 2028
University Medical Center GroningenHydrochlorothiazide
Thiazide-sensitive sodium-chloride cotransporter inhibitor
SLC12A3Phase 3ADPKDJul 2030
Tanta Universitymetolazone
Thiazide-sensitive sodium-chloride cotransporter inhibitor
SLC12A3Phase 2Acute Decompensated Heart FailureFeb 2027
Insel Gruppe AG, University Hospital BernChlorthalidone
Thiazide-sensitive sodium-chloride cotransporter inhibitor
SLC12A3Phase 2Kidney StoneJun 2027
Insel Gruppe AG, University Hospital BernIndapamide
Thiazide-sensitive sodium-chloride cotransporter inhibitor
SLC12A3Phase 2Kidney StoneJun 2027

Conditions

Kidney Stone (2) ADPKD (1) Kidney Stones (1) Hypertension (1) Acute Decompensated Heart Failure (1) Acute Heart Failure (1) Hypoparathyroidism Post-surgical (1)

Modalities

small molecule (8)

Companies

Insel Gruppe AG, University Hospital Bern (2) University Medical Center Groningen (1) Icahn School of Medicine at Mount Sinai (1) Chinese University of Hong Kong (1) Tanta University (1) Johannes Grand (1) Lars Rejnmark (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.